On the equivariant algebraic Jacobian for curves of genus two

We present a treatment of the algebraic description of the Jacobian of a generic genus two plane curve which exploits an SL2(k) equivariance and clarifes the structure of E.V.Flynn's 72 defining quadratic relations. The treatment is also applied to the Kummer variety

Fundamental principles of classical mechanics: a geometrical perspective

No abstract available

Building Abelian Functions with Generalised Baker-Hirota Operators

We present a new systematic method to construct Abelian functions on Jacobian varieties of plane, algebraic curves. The main tool used is a symmetric generalisation of the bilinear operator defined in the work of Baker and Hirota. We give explicit formulae for the multiple applications of the operators, use them to define infinite sequences of Abelian functions of a prescribed pole structure and deduce the key properties of these functions. We apply the theory on the two canonical curves of genus three, presenting new explicit examples of vector space bases of Abelian functions. These reveal previously unseen similarities between the theories of functions associated to curves of the same genus

Equivariance in the Theory of Higher Genus ℘-Functions

We discuss a synthetic use of symmetry in two constructions of relations between functions on curves and their Jacobians

Laplace maps and constraints for a class of third order partial differential operators

We explore the existence of a class of generalised Laplace maps for third order partial differential operators of the form @1@2@3 + a1@2@3 + a2@1@3 + a3@1@2 + a12@3 + a23@1 + a13@2 + a123 and related first order 3 systems and show that they require the satisfaction of constraints on the invariants for such operators

Twisted laplace maps

We consider general Darboux maps arising from intertwining relations on second order, linear partial differential operators, as deformations of the classical, Laplace case. We present Lax pairs for the corresponding relations on invariants and discuss the conditions for a lattice structure analogous to 2D Toda theory

Equivariance and algebraic relations for curves

We generalise a classical argument for deducing algebraic models of Riemann surfaces from the Riemann–Roch theorem. The method involves counting arguments based on equivariant resolutions

Generalised Elliptic Functions

We consider multiply periodic functions, sometimes called Abelian functions, defined with respect to the period matrices associated with classes of algebraic curves. We realise them as generalisations of the Weierstras P-function using two different approaches. These functions arise naturally as solutions to some of the important equations of mathematical physics and their differential equations, addition formulae, and applications have all been recent topics of study. The first approach discussed sees the functions defined as logarithmic derivatives of the sigma-function, a modified Riemann theta-function. We can make use of known properties of the sigma function to derive power series expansions and in turn the properties mentioned above. This approach has been extended to a wide range of non hyperelliptic and higher genus curves and an overview of recent results is given. The second approach defines the functions algebraically, after first modifying the curve into its equivariant form. This approach allows the use of representation theory to derive a range of results at lower computational cost. We discuss the development of this theory for hyperelliptic curves and how it may be extended in the future.Comment: 16 page

Identities for hyperelliptic P-functions of genus one, two and three in covariant form

We give a covariant treatment of the quadratic differential identities satisfied by the P-functions on the Jacobian of smooth hyperelliptic curves of genera 1, 2 and 3

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication